JP2017502081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502081A5 JP2017502081A5 JP2016557194A JP2016557194A JP2017502081A5 JP 2017502081 A5 JP2017502081 A5 JP 2017502081A5 JP 2016557194 A JP2016557194 A JP 2016557194A JP 2016557194 A JP2016557194 A JP 2016557194A JP 2017502081 A5 JP2017502081 A5 JP 2017502081A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- ras protein
- substitution
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 134
- 238000006467 substitution reaction Methods 0.000 claims 69
- 102000016914 ras Proteins Human genes 0.000 claims 52
- 108010014186 ras Proteins Proteins 0.000 claims 51
- 125000003275 alpha amino acid group Chemical group 0.000 claims 44
- 239000000203 mixture Substances 0.000 claims 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 150000001413 amino acids Chemical class 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 16
- 230000028993 immune response Effects 0.000 claims 12
- 238000002360 preparation method Methods 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229960005486 vaccine Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 102200006657 rs104894228 Human genes 0.000 claims 6
- 102200006533 rs121913535 Human genes 0.000 claims 5
- 102200006537 rs121913529 Human genes 0.000 claims 4
- 102200006540 rs121913530 Human genes 0.000 claims 4
- 102200006541 rs121913530 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102200006532 rs112445441 Human genes 0.000 claims 3
- 102220014333 rs112445441 Human genes 0.000 claims 3
- 102200006520 rs121913240 Human genes 0.000 claims 3
- 102200006525 rs121913240 Human genes 0.000 claims 3
- 102200006531 rs121913529 Human genes 0.000 claims 3
- 102200006539 rs121913529 Human genes 0.000 claims 3
- 102200006538 rs121913530 Human genes 0.000 claims 3
- 102200007373 rs17851045 Human genes 0.000 claims 3
- 102200006648 rs28933406 Human genes 0.000 claims 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 102220117341 rs11554290 Human genes 0.000 claims 2
- 102220197780 rs121434596 Human genes 0.000 claims 2
- 102220197778 rs121913254 Human genes 0.000 claims 2
- 102220197834 rs121913535 Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- -1 T cell preparations Substances 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 210000003192 autonomic ganglia Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196333 | 2013-12-09 | ||
| EP13196333.2 | 2013-12-09 | ||
| PCT/EP2014/077033 WO2015086590A2 (en) | 2013-12-09 | 2014-12-09 | A peptide mixture |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019183442A Division JP2020023525A (ja) | 2013-12-09 | 2019-10-04 | ペプチド混合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502081A JP2017502081A (ja) | 2017-01-19 |
| JP2017502081A5 true JP2017502081A5 (enExample) | 2018-01-25 |
| JP6781403B2 JP6781403B2 (ja) | 2020-11-04 |
Family
ID=49765823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557194A Active JP6781403B2 (ja) | 2013-12-09 | 2014-12-09 | ペプチド混合物 |
| JP2019183442A Pending JP2020023525A (ja) | 2013-12-09 | 2019-10-04 | ペプチド混合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019183442A Pending JP2020023525A (ja) | 2013-12-09 | 2019-10-04 | ペプチド混合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9775892B2 (enExample) |
| EP (5) | EP3363458A3 (enExample) |
| JP (2) | JP6781403B2 (enExample) |
| KR (1) | KR20160097290A (enExample) |
| CN (1) | CN105980403A (enExample) |
| AU (2) | AU2014363643B2 (enExample) |
| BR (1) | BR112016013138A2 (enExample) |
| CA (1) | CA2933126A1 (enExample) |
| CL (4) | CL2016001405A1 (enExample) |
| CY (1) | CY1120578T1 (enExample) |
| DK (1) | DK3079715T3 (enExample) |
| ES (1) | ES2682038T3 (enExample) |
| HR (1) | HRP20181213T1 (enExample) |
| HU (1) | HUE039840T2 (enExample) |
| IL (1) | IL246007B2 (enExample) |
| LT (1) | LT3079715T (enExample) |
| MX (1) | MX2016007429A (enExample) |
| PL (1) | PL3079715T3 (enExample) |
| PT (1) | PT3079715T (enExample) |
| RS (1) | RS57623B1 (enExample) |
| RU (1) | RU2016127327A (enExample) |
| SG (2) | SG10201811172PA (enExample) |
| SI (1) | SI3079715T1 (enExample) |
| WO (1) | WO2015086590A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| CN106414493A (zh) | 2014-05-06 | 2017-02-15 | 塔格瓦克斯公司 | 包含突变的ras肽和化疗剂的肽疫苗 |
| EP3576780A1 (en) | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| AU2018288386A1 (en) * | 2017-06-22 | 2020-02-06 | New South Wales Health Pathology | Adoptive T cell therapy 2 |
| CA3103983A1 (en) * | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| JP2021534752A (ja) * | 2018-08-22 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法 |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
| US12453774B2 (en) | 2019-11-07 | 2025-10-28 | Genoimmune Therapeutics Co., Ltd. | Tumor immunotherapy polypeptide and application thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| KR102515083B1 (ko) | 2020-12-24 | 2023-03-29 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
| EP4293043A4 (en) * | 2021-02-10 | 2025-09-10 | Shanghai Genbase Biotechnology Co Ltd | EPITOPE PEPTIDE OF THE RAS G13D MUTANT AND T LYMPHOCYTE RECEPTOR RECOGNIZING THE RAS G13D MUTANT |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| EP4522192A2 (en) * | 2022-05-12 | 2025-03-19 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| JP2025538524A (ja) * | 2022-11-22 | 2025-11-28 | エリクサージェン セラピューティクス，インコーポレイティド | 癌免疫療法のための抗原 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| PL1760089T3 (pl) | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| CN101448848B (zh) * | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| CN106414493A (zh) | 2014-05-06 | 2017-02-15 | 塔格瓦克斯公司 | 包含突变的ras肽和化疗剂的肽疫苗 |
-
2014
- 2014-12-09 US US15/102,681 patent/US9775892B2/en not_active Expired - Fee Related
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Withdrawn
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en not_active Withdrawn
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en not_active Ceased
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en not_active Withdrawn
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en not_active Ceased
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en not_active Withdrawn
-
2016
- 2016-06-02 IL IL246007A patent/IL246007B2/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en not_active Ceased
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502081A5 (enExample) | ||
| RU2016127327A (ru) | Смесь пептидов | |
| RU2018101225A (ru) | Мутированные фрагменты белка ras | |
| Syn et al. | De-novo and acquired resistance to immune checkpoint targeting | |
| Fiorica et al. | Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination | |
| RU2016147527A (ru) | Пептидная вакцина, включающая пептид ras, содержащий мутации, и химиотерапевтический агент | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| CL2022002836A1 (es) | Polipeptidos derivados de cancer (divisional 201902533) | |
| Obara et al. | Present status and future perspective of peptide‐based vaccine therapy for urological cancer | |
| BR112017017560A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere | |
| BR112017017289A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra diversos tumores | |
| JP2017514847A5 (enExample) | ||
| BR112017023362A2 (pt) | peptídeos e combinação de peptídeos e arcabouços dos mesmos para uso na imunoterapia contra o carcinoma colorretal (crc) e outros cânceres | |
| MX377144B (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| BR112018003460A2 (pt) | peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres | |
| Tagliamonte et al. | Potentiating cancer vaccine efficacy in liver cancer | |
| BR112017019217A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pâncreas e outros cânceres | |
| BR112018001687A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de próstata e outros cânceres | |
| BR112018067989A2 (pt) | células t transfectadas e receptores de células t para uso em imunoterapia anticâncer | |
| NZ714163A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| BR112019003513A2 (pt) | peptídeos e suportes para uso em imunoterapia de carcinoma de células escamosas de cabeça e pescoço e outros cânceres | |
| JP2015529676A5 (enExample) | ||
| Zhu et al. | Personalised neoantigen‐based therapy in colorectal cancer | |
| BR112018068489A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia anticâncer | |
| CL2022000642A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres (divisional de la solicitud no. 202000020) |